A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

Completed · Phase 2 · Has a placebo group

Conditions studied: Psoriatic Arthritis

In brief

This is a study to evaluate the dose response based on the efficacy, safety and tolerability of bimekizumab in subjects with active psoriatic arthritis.

Key facts

Study ID

NCT02969525

Run by

UCB Biopharma S.P.R.L.

People needed

206

Starts

2016-10-01

Expected to finish

2018-07-01

Last updated by the study team

2023-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has a documented diagnosis of adult-onset PsA classified by Classification Criteria for Psoriatic Arthritis (CASPAR) criteria with symptoms for at least 6 months prior to Screening, with active psoriatic arthritis (PsA) at Baseline/Day 1, and must have at Baseline tender joint count (TJC) >=3 out of 78 and swollen joint count (SJC) >=3 out of 76
• Subject must be rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies negative
• Subject must have active psoriatic lesion(s) and/or a documented history of psoriasis
• Subjects who are regularly taking nonsteroidal anti-inflammatory drug (NSAIDs)/COX-2 inhibitors as part of their PsA therapy are required to be on a stable dose/dose regimen for at least 14 days before Baseline
• Subjects taking corticosteroids must be on an average daily dose of <=10mg/day prednisone or equivalent for at least 14 days before Baseline and should remain on a stable dose through the Week 16 visit
• Subjects taking methotrexate (MTX) (<=25mg /week) are allowed to continue their medication if started at least 12 weeks prior to Baseline, with a stable dose for at least 8 weeks before randomization
• Subjects taking leflunomide (LEF; <=20mg/day or an average of 20mg/day if not dosed daily) are allowed to continue their medication if started at least 3 months prior to Baseline, with a stable dose for at least 8 weeks before randomization. Dose and dosing schedule should remain stable up to Week 16
• Subjects may be tumor necrosis factor (TNF) inhibitor naïve or may have received 1 prior TNF inhibitor. Subjects who have been on a TNF inhibitor previously must have:
• experienced an inadequate response to previous treatment given for at least 3 months
• been intolerant to administration (eg, had a side-effect/adverse event (AE) that led to discontinuation)
• lost access to TNF inhibitor for other reasons

You may not qualify if…

• Subjects with any current sign or symptom that may indicate an active infection (with the exception of the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of Baseline/Day 1
• Subjects with a history of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months prior to the Baseline Visit
• Subjects with concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection
• Subjects with known history of or current clinically active infection with Histoplasma, Coccidioides, Paracoccidioides, Pneumocystis, Blastomyces, or Aspergillus or current active Candidiasis
• Subjects receiving any live (includes attenuated) vaccination within the 8 weeks prior to Baseline
• Subjects with known tuberculosis (TB) infection, at high risk of acquiring TB infection, with latent TB infection (LTBI), or current or history of nontuberculous mycobacteria (NTMB) infection
• Subjects with a diagnosis of inflammatory conditions other than psoriasis or psoriatic arthritis
• Subjects with concurrent malignancy or a history of malignancy during the past 5 years will be excluded, with following exceptions that may be included:
• <= 3 excised or ablated basal cell carcinomas of the skin
• One squamous cell carcinoma of the skin (stage T1 maximum) successfully excised, or ablated only (other treatments, ie, chemotherapy, do not apply), with no signs of recurrence or metastases for more than 2 years prior to Screening
• Actinic keratosis (-es)
• Squamous cell carcinoma-in-situ of the skin successfully excised, or ablated, more than 6 months prior to Screening

Where it is running

• Pa0008 007 — San Diego, California, United States
• Pa0008 005 — Aventura, Florida, United States
• Pa0008 003 — Hagerstown, Maryland, United States
• Pa0008 011 — Lansing, Minnesota, United States
• Pa0008 025 — Lexington, New York, United States
• Pa0008 014 — Portland, Oregon, United States
• Pa0008 001 — Duncansville, Pennsylvania, United States
• Pa0008 012 — Johnston, Rhode Island, United States
• Pa0008 004 — Charleston, South Carolina, United States
• Pa0008 010 — Jackson, Tennessee, United States
• Pa0008 006 — Dallas, Texas, United States
• Pa0008 013 — Mesquite, Texas, United States
• Pa0008 002 — Seattle, Washington, United States
• Pa0008 205 — Brno, Czechia
• Pa0008 207 — Olomouc, Czechia
• Pa0008 201 — Prague, Czechia
• Pa0008 202 — Prague, Czechia
• Pa0008 209 — Prague, Czechia
• Pa0008 210 — Prague, Czechia
• Pa0008 203 — Zlín, Czechia
• Pa0008 302 — Cologne, Germany
• Pa0008 309 — Erlangen, Germany
• Pa0008 304 — Hamburg, Germany
• Pa0008 301 — Ratingen, Germany
• Pa0008 403 — Budakeszierdő, Hungary

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.